文献检索
文档翻译
深度研究
Zotero 插件
邀请有礼
套餐&价格
历史记录
Suppr
超能文献
应用&插件
FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer.
出版信息
J Nucl Med. 2022 May;63(5):13N.
PMID:
35487569
Abstract
摘要
文献AI研究员
20分钟写一篇综述，助力文献阅读效率提升50倍。
立即体验
用中文搜PubMed
大模型驱动的PubMed中文搜索引擎
马上搜索
文档翻译
学术文献翻译模型，支持多种主流文档格式。
立即体验
应用&插件
Zotero 插件
浏览器插件
Mac 客户端
Windows 客户端
微信小程序
定价
高级版会员
购买积分包
购买API积分包
服务
文献检索
文档翻译
深度研究
API 文档
MCP 服务
关于我们
关于 Suppr
公司介绍
联系我们
用户协议
隐私条款
关注我们
Suppr 超能文献
核心技术专利：
CN118964589B
侵权必究
粤ICP备2023148730 号-1
Suppr @ 2026
相似文献
1
FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer.
美国食品药品监督管理局批准Pluvicto/Locametz用于治疗转移性去势抵抗性前列腺癌。
J Nucl Med. 2022 May;63(5):13N.
2
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
反驳观点：在有症状的转移性去势抵抗性前列腺癌中，多西他赛和镭-223应首先使用哪一种？镭-223是骨转移为主的有症状转移性去势抵抗性前列腺癌的首选治疗方法。
Clin Adv Hematol Oncol. 2015 May;13(5):293-8.
3
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
对立观点：在有症状的转移性去势抵抗性前列腺癌中，多西他赛和镭-223哪个应首先使用？多西他赛仍是有症状的转移性去势抵抗性前列腺癌的最佳首选。
Clin Adv Hematol Oncol. 2015 May;13(5):293-5.
4
Metastatic castration-resistant prostate cancer therapy: the quest for the perfect molecule.
转移性去势抵抗性前列腺癌治疗：对完美分子的探索。
Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):883-884. doi: 10.1007/s00259-023-06506-8.
5
[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
[镥]-PSMA-617 放射性核素治疗转移性去势抵抗性前列腺癌患者（LuPSMA 试验）：一项单中心、单臂、2 期研究。
Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.
6
Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223.
用镭-223治疗转移性去势抵抗性前列腺癌后发生的急性早幼粒细胞白血病
Clin Genitourin Cancer. 2017 Jun;15(3):e501-e502. doi: 10.1016/j.clgc.2016.12.028. Epub 2016 Dec 29.
7
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.
Bi-PSMA-617靶向α放射性核素疗法治疗转移性去势抵抗性前列腺癌
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.
8
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing Lu-PSMA Therapy.
接受镥-PSMA治疗的去势抵抗性转移性前列腺癌患者反应和总生存期的预测因素
J Nucl Med. 2018 Jul;59(7):1033-1034. doi: 10.2967/jnumed.118.209270. Epub 2018 Apr 13.
9
[The modern treatment of metastatic castration-resistant prostate cancer].
[转移性去势抵抗性前列腺癌的现代治疗]
Magy Onkol. 2019 Mar 19;63(1):41-50. Epub 2019 Jan 2.
10
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.
局部区域治疗去势抵抗性前列腺癌：是否有任何依据？来自 AFU-GETUG 的批判性回顾。
Crit Rev Oncol Hematol. 2018 Feb;122:144-149. doi: 10.1016/j.critrevonc.2017.12.012. Epub 2017 Dec 30.
引用本文的文献
1
Evaluating the Potential of PSMA Targeting in CNS Tumors: Insights from Large-Scale Transcriptome Profiling.
评估PSMA靶向在中枢神经系统肿瘤中的潜力：来自大规模转录组分析的见解
Cancers (Basel). 2025 Apr 6;17(7):1239. doi: 10.3390/cancers17071239.
2
Interactions between key genes and pathways in prostate cancer progression and therapy resistance.
前列腺癌进展和治疗抵抗中关键基因与信号通路之间的相互作用。
Front Oncol. 2025 Jan 23;15:1467540. doi: 10.3389/fonc.2025.1467540. eCollection 2025.
3
Safety, Dosimetry, and Feasibility of [Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
[镓]Ga-PSMA-R2作为生化复发或转移性前列腺癌患者成像剂的安全性、剂量学及可行性
J Nucl Med. 2025 Mar 3;66(3):359-365. doi: 10.2967/jnumed.124.268318.
4
Novel astatine (At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model.
具有新戊二醇结构的新型砹（At）标记的前列腺特异性膜抗原配体：使用前列腺癌异种移植模型评估其稳定性、疗效和安全性。
Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):469-481. doi: 10.1007/s00259-024-06945-x. Epub 2024 Oct 12.
5
Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?
转移性去势抵抗性前列腺癌的治疗反应评估：PSMA-PET/CT会成为主导吗？
Ther Adv Med Oncol. 2024 Oct 7;16:17588359241258367. doi: 10.1177/17588359241258367. eCollection 2024.
6
Unveiling the Potential of Prostate-Specific Membrane Antigen for Precision Diagnosis and Therapy of Prostate Cancer: A Radiopharmaceutical Perspective.
从放射性药物角度揭示前列腺特异性膜抗原在前列腺癌精准诊断与治疗中的潜力
Malays J Med Sci. 2024 Aug;31(4):213-217. doi: 10.21315/mjms2024.31.4.17. Epub 2024 Aug 27.
7
PSMA-Targeted 2-Deoxyglucose-Based Dendrimer Nanomedicine for the Treatment of Prostate Cancer.
PSMA 靶向 2-脱氧葡萄糖基树状纳米医学用于治疗前列腺癌。
Biomacromolecules. 2024 Sep 9;25(9):6164-6180. doi: 10.1021/acs.biomac.4c00878. Epub 2024 Aug 20.
8
Synthesis of Cu-, Co-, and Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles.
合成用于神经降压素受体 1 靶向治疗学的 Cu、Co 和 Ga 标记放射性药物：使用多胺大环调整体内分布。
J Nucl Med. 2024 Aug 1;65(8):1250-1256. doi: 10.2967/jnumed.124.267469.
9
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
用于治疗肺癌的药物偶联物：从药物发现到临床实践
Exp Hematol Oncol. 2024 Mar 1;13(1):26. doi: 10.1186/s40164-024-00493-8.
10
Optimization and scale up of production of the PSMA imaging agent [F]AlF-P16-093 on a custom automated radiosynthesis platform.
在定制的自动化放射性合成平台上对PSMA成像剂[F]AlF-P16-093进行生产优化及扩大规模
EJNMMI Radiopharm Chem. 2024 Feb 23;9(1):15. doi: 10.1186/s41181-024-00247-1.
Zotero 插件